Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN ES 600 versus PENAPAR VK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN ES 600 versus PENAPAR VK.
AUGMENTIN ES-600 vs PENAPAR-VK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AUGMENTIN ES-600 is a combination of amoxicillin, a beta-lactam antibiotic, and clavulanate, a beta-lactamase inhibitor. Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), while clavulanate irreversibly inhibits beta-lactamase enzymes, preventing degradation of amoxicillin.
Penicillin V is a bactericidal antibiotic that inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
90 mg/kg/day orally divided every 12 hours (based on amoxicillin component). Maximum 4000 mg amoxicillin/600 mg clavulanate per day.
250-500 mg orally every 6 hours; maximum 2 g/day.
None Documented
None Documented
Amoxicillin: ~1.0-1.5 hours in adults with normal renal function; clavulanate: ~1.0-1.2 hours. In renal impairment, half-life prolongs significantly (amoxicillin up to 7-20 hours in ESRD).
Terminal elimination half-life: 0.5–1 hour in normal renal function; prolonged to 7–10 hours in severe renal impairment (anuria). Requires dose adjustment in renal failure.
Amoxicillin: ~50-70% excreted unchanged renally via glomerular filtration and tubular secretion; clavulanate: ~25-40% excreted unchanged renally. Combined: renal excretion accounts for ~60-80% of elimination, with minor biliary/fecal elimination (approx 5-15% for amoxicillin).
Primarily renal excretion (tubular secretion) of unchanged drug (~90%); minor biliary/fecal elimination (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic